| Polycythemia Vera
Jakafi vs Besremi
Side-by-side clinical, coverage, and cost comparison for polycythemia vera.Deep comparison between: Jakafi vs Besremi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBesremi has a higher rate of injection site reactions vs Jakafi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Besremi but not Jakafi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jakafi
Besremi
At A Glance
Oral
Twice daily
JAK1/JAK2 inhibitor
SC injection
Every 2-4 weeks
Interferon alfa
Indications
- Myelofibrosis
- Polycythemia Vera
- Acute GVH disease
- Chronic graft-versus-host disease
- Polycythemia Vera
Dosing
Myelofibrosis Starting dose based on platelet count: 20 mg orally twice daily (>200 x 10^9/L), 15 mg twice daily (100-200 x 10^9/L), or 5 mg twice daily (50 to <100 x 10^9/L); doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Polycythemia Vera 10 mg orally twice daily starting dose; doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Acute GVH disease 5 mg orally twice daily starting dose; may increase to 10 mg twice daily after at least 3 days if ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing.
Chronic graft-versus-host disease 10 mg orally twice daily starting dose; taper after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids.
Polycythemia Vera Starting dose 100 mcg SC every 2 weeks (not on hydroxyurea) or 50 mcg SC every 2 weeks (transitioning from hydroxyurea); titrate by 50 mcg every 2 weeks to a maximum of 500 mcg until hematological parameters are stabilized; after at least 1 year of hematological stability on a stable dose, dosing interval may be expanded to every 4 weeks.
Contraindications
—
- Existence of, or history of, severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt
- Hypersensitivity to interferons including interferon alfa-2b or any inactive ingredient of BESREMi
- Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
- History or presence of active serious or untreated autoimmune disease
- History of transplantation and receiving immunosuppressant agents
Adverse Reactions
Most common Thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache, infections, edema, hemorrhage, fatigue
Serious Thrombocytopenia, anemia, neutropenia, infections, non-melanoma skin cancer, major adverse cardiovascular events, thrombosis, secondary malignancies
Postmarketing Herpes simplex virus reactivation and/or dissemination
Most common (>10%) Liver enzyme elevations, leukopenia, thrombocytopenia, arthralgia, fatigue, myalgia, influenza-like illness
Serious Urinary tract infection, transient ischemic attack, depression
Pharmacology
Ruxolitinib is a kinase inhibitor that selectively inhibits JAK1 and JAK2, which mediate cytokine and growth factor signaling important for hematopoiesis and immune function; dysregulated JAK1/JAK2 signaling underlies myelofibrosis, polycythemia vera, and GVHD pathogenesis.
Ropeginterferon alfa-2b-njft is a type I interferon that binds to the interferon alfa receptor (IFNAR) on bone marrow cells, activating JAK1, TYK2, and STAT signaling pathways to control gene-expression programs involved in the treatment of polycythemia vera.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jakafi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
Besremi
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Jakafi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (7/8)
Besremi
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (2/8) · Qty limit (3/8)
Humana
Jakafi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Besremi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jakafi.
Cost estimate not availableCancerCare: Myeloproliferative Neoplasms
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JakafiView full Jakafi profile
BesremiView full Besremi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.